问题 › 增长却在亏损 › HealthTech & Digital Health
增长消耗现金，要么是对归因结果的投资，要么是风险份额的泄漏，算术在一页内就能告诉你哪一种。 数字健康公司面临更难的结构性问题：结果风险签约速度快于公司能否承担得起的学习速度——12个月测量窗口对11个月销售周期。因此任何可信答案都必须把风险收入份额和参与率放在同一视图中，而这正是大多数内部分析停滞的地方，因为两者存在于不同系统。
增长消耗现金，要么是对归因结果的投资，要么是风险份额的泄漏，算术在一页内就能告诉你哪一种。 数字健康公司面临更难的结构性问题：结果风险签约速度快于公司能否承担得起的学习速度——12个月测量窗口对11个月销售周期。因此任何可信答案都必须把风险收入份额和参与率放在同一视图中，而这正是大多数内部分析停滞的地方，因为两者存在于不同系统。
增长同时亏损是正常的，如果每新增一名入组成员最终能带来归因结果，收回风险份额。它是致命的，如果参与率阻止回收，而只要销售周期还在持续，两者看起来完全相同——这就是为什么失败通常在增长停止、测量窗口到来时才被发现。
测试以每名入组成员为单位，简单直接：多一名成员的获取和参与服务成本是多少PMPM，他们能返回多少风险份额和毛利率，以及在多长时间内。如果结果为正且亏损是固定成本吸收，增长就能解决。如果为负，增长只会加速问题，每多一名成员都会让处境更糟。
第二要检查的是营运资金。企业可能在归因结果上显示正的每成员经济，但仍会耗尽现金，因为资金支出早于结果付款数月——增长越快，缺口就越大。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ ARR上升，现金下降，两者被分开解释
✓ 没人能不靠项目就说出每名入组成员来自风险份额、参与率和客户流失的贡献毛利
✓ 融资需求不断早于预测出现
通常会让情况更糟的做法。 把亏损当作规模问题处理，而单位经济其实为负，这会把可修复的模式变成更大的问题。
It is for you if you run or finance a digital health company and revenue rises, cash falls, and the two are explained separately. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 专有EFF方法论, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
当亏损是固定成本被吸收且单位经济为正时，是正常的。当每增加一名客户都在亏损时，不是正常的——这是同一外表下的不同情况。
按预期量级推演当前单位经济，看曲线是否交叉。如果在你能合理达到的量级上不交叉，增长就不是答案。
如果单位经济为负，是的，而且要立即。如果为正且约束是营运资金，问题在于融资而非战略，应按此解决。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית